Highlights of This Issue  807

CELL DEATH AND SURVIVAL

809 HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer
Huaieng Zhu, Zuzana Berkova, Rohit Mathur, Lalit Sehgal, Tamer Khashab, Rong-Hua Tao, Xue Ao, Lei Feng, Anita L. Sabichi, Boris Blechacz, Asif Rashid, and Felipe Samaniego

819 Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies
Jerome T. Higgs, John S. Jarboe, Joo Hyoung Lee, Diptiman Chanda, Carnellia M. Lee, Champion Deivanayagam, and Selvarangan Ponnazhagan

CHROMATIN, GENE, AND RNA REGULATION

828 The IncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus
Kouhei Sakurai, Brian J. Reon, Jordan Anaya, and Anindya Dutta

839 LncRNA Expression Discriminates Karyotype and Predicts Survival in B-Lymphoblastic Leukemia
Thilini R. Fernando, Norma I. Rodriguez-Malave, Ella V. Waters, Weihong Yan, David Casero, Giuseppe Basso, Martina Pigazzi, and Dinesh S. Rao

DNA DAMAGE AND REPAIR

852 Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins
Uday Bhanu Maachani, Tamalee Kramp, Ryan Hanson, Shuping Zhao, Orieta Celiku, Ulma Shankavaram, Riccardo Colombo, Natasha J. Caplen, Kevin Camphausen, and Anita Tandle

GENOMICS

863 Detection of Tumor Suppressor Genes in Cancer Development by a Novel shRNA-Based Method
Johannes von Burstin, Sandra Diersch, Günter Schneider, Maximilian Reichert, Anil K. Rustgi, and Roland M. Schmid

870 Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome
Leiping Fu, Denise R. Minton, Tao Zhang, David M. Nanus, and Lorraine J. Gudas

ONCOGENES AND TUMOR SUPPRESSORS

879 Tumor Suppressor NF2 Blocks Cellular Migration by Inhibiting Ectodomain Cleavage of CD44
Monika Hartmann, Liseth M. Parra, Anne Ruschel, Sandra Böhme, Yong Li, Helen Morrison, Andreas Herrlich, and Peter Herrlich

891 Breast Cancer-Specific miR Signature Unique to Extracellular Vesicles Includes "microRNA-like" tRNA Fragments
Nicole Guzman, Kitty Agarwal, Dilip Asthagiri, Lianbo Yu, Motoyasu Saji, Matthew D. Ringel, and Michael E. Paulaitis

902 The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells
Perla El-Hage, Ambre Petitalot, Anne-Hélène Monsoro-Burq, Frédérique Maczkowiak, Keltouma Driouch, Etienne Formstecher, Jacques Camonis, Michèle Sabbah, Ivan Biche, Rosette Lidereau, and François Lallemand

913 The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase
Liang-Nian Song, Jose Silva, Antonius Koller, Andrew Rosenthal, Emily I. Chen, and Edward P. Gelmann
mTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer
Valerie L. Sodi, Sakina Khaku, Raisa Krutilina, Luciana P. Schwab, David J. Vocadlo, Tiffany N. Seagroves, and Mauricio J. Reginato

MAPK7 Regulates EMT Features and Modulates the Generation of CTCs
Sarah Javaid, Jianmin Zhang, Gromoslaw A. Smolen, Min Yu, Ben S. Wittner, Anurag Singh, Kshitij S. Arora, Marissa W. Madden, Rushil Desai, Matthew J. Zubrowski, Benjamin J. Schott, David T. Ting, Shannon L. Stott, Mehmet Toner, Shyamala Maheswaran, Toshi Shioda, Sridhar Ramaswamy, and Daniel A. Haber

Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells
Uri Rozovski, Srdana Grgurevic, Carlos Bueso-Ramos, David M. Harris, Ping Li, Zhiming Liu, Ji Yuan Wu, Preetesh Jain, William Wierda, Jan Burger, Susan O’Brien, Nitin Jain, Alessandra Ferrajoli, Michael J. Keating, and Zeev Estrov

Epithelial-to-mesenchymal transition (EMT) has been implicated in tumor cell migration, invasion, and metastasis. Suppression of MAPK7 increases E-cadherin (CDH1) expression, inhibits cell migration, and reduces circulating tumor cells and the appearance of lung metastases. The cover shows immunofluorescent staining of A549 cancer cells following knockdown of MAPK7, showing increased expression of CDH1 localized to the cell membrane (CDH1, green; Vimentin, red; DAPI, blue). Please see the article by Javaid and colleagues (beginning on page 934) for more information.